Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Biomarkers that predict and guide therapy for exacerbations of chronic obstructive pulmonary disease.

Brightling CE.

Ann Am Thorac Soc. 2013 Dec;10 Suppl:S214-9. doi: 10.1513/AnnalsATS.201302-023AW. Review.

PMID:
24313775
2.

Procalcitonin-guided antibiotic therapy for chronic obstructive pulmonary disease exacerbations.

Tokman S, Schuetz P, Bent S.

Expert Rev Anti Infect Ther. 2011 Jun;9(6):727-35. doi: 10.1586/eri.11.45. Review.

PMID:
21692680
3.

Procalcitonin-guided antibiotic therapy in COPD exacerbations: closer but not quite there.

Martinez FJ, Curtis JL.

Chest. 2007 Jan;131(1):1-2. No abstract available.

PMID:
17218546
4.

Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy.

Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Müller C, Huber P, Müller B, Tamm M.

Chest. 2007 Jan;131(1):9-19.

PMID:
17218551
5.

Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.

Thomsen M, Ingebrigtsen TS, Marott JL, Dahl M, Lange P, Vestbo J, Nordestgaard BG.

JAMA. 2013 Jun 12;309(22):2353-61. doi: 10.1001/jama.2013.5732.

PMID:
23757083
6.

Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD.

Soler N, Esperatti M, Ewig S, Huerta A, Agustí C, Torres A.

Eur Respir J. 2012 Dec;40(6):1344-53. doi: 10.1183/09031936.00150211. Epub 2012 Apr 20.

7.

Exacerbations of chronic obstructive pulmonary disease.

Wedzicha JA, Donaldson GC.

Respir Care. 2003 Dec;48(12):1204-13; discussion 1213-5. Review.

8.

Procalcitonin and C-reactive protein cannot differentiate bacterial or viral infection in COPD exacerbation requiring emergency department visits.

Chang CH, Tsao KC, Hu HC, Huang CC, Kao KC, Chen NH, Yang CT, Tsai YH, Hsieh MJ.

Int J Chron Obstruct Pulmon Dis. 2015 Apr 13;10:767-74. doi: 10.2147/COPD.S76740. eCollection 2015.

9.

Mechanisms of Chronic Obstructive Pulmonary Disease Exacerbations.

Wedzicha JA.

Ann Am Thorac Soc. 2015 Nov;12 Suppl 2:S157-9. doi: 10.1513/AnnalsATS.201507-427AW.

PMID:
26595732
10.

Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers.

Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, McCormick M, Haldar K, Kebadze T, Duvoix A, Lindblad K, Patel H, Rugman P, Dodson P, Jenkins M, Saunders M, Newbold P, Green RH, Venge P, Lomas DA, Barer MR, Johnston SL, Pavord ID, Brightling CE.

Am J Respir Crit Care Med. 2011 Sep 15;184(6):662-71. doi: 10.1164/rccm.201104-0597OC.

PMID:
21680942
11.

[Role of antibiotherapy in acute exacerbation of chronic obstructive pulmonary disease].

Cavassini M, Calandra T, Bridevaux PO.

Rev Med Suisse. 2007 Apr 11;3(106):939-42. Review. French.

PMID:
17575969
12.

Antibiotic treatment of severe exacerbations of chronic obstructive pulmonary disease with procalcitonin: a randomized noninferiority trial.

Verduri A, Luppi F, D'Amico R, Balduzzi S, Vicini R, Liverani A, Ruggieri V, Plebani M, Barbaro MP, Spanevello A, Canonica GW, Papi A, Fabbri LM, Beghè B; FARM58J2XH Study Group..

PLoS One. 2015 Mar 11;10(3):e0118241. doi: 10.1371/journal.pone.0118241. eCollection 2015.

13.
14.

[Procalcitonin as a biomarker in infections].

Christ-Crain M.

Praxis (Bern 1994). 2007 Jun 20;96(25-26):1017-21. Review. German. No abstract available.

PMID:
17639964
15.

Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B.

Lancet. 2004 Feb 21;363(9409):600-7.

PMID:
14987884
16.

Pharmacotherapy for lower respiratory tract infections.

Liapikou A, Torres A.

Expert Opin Pharmacother. 2014 Nov;15(16):2307-18. doi: 10.1517/14656566.2014.959927. Epub 2014 Sep 12. Review. Erratum in: Expert Opin Pharmacother. 2014 Dec;15(18):2755. Adamantia, Liapikou [corrected to Liapikou, Adamantia]; Torres, Antonio [corrected to Torres, Antoni].

PMID:
25216725
17.

Procalcitonin and C-reactive protein in hospitalized adult patients with community-acquired pneumonia or exacerbation of asthma or COPD.

Bafadhel M, Clark TW, Reid C, Medina MJ, Batham S, Barer MR, Nicholson KG, Brightling CE.

Chest. 2011 Jun;139(6):1410-8. doi: 10.1378/chest.10-1747. Epub 2010 Oct 28.

18.

[COPD and bacterial colonization: therapeutic implications].

Gómez J, Baños V, García Martín E.

Rev Esp Quimioter. 2005 Jun;18(2):187-91. Spanish. No abstract available.

19.

Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note.

Falsey AR, Becker KL, Swinburne AJ, Nylen ES, Snider RH, Formica MA, Hennessey PA, Criddle MM, Peterson DR, Walsh EE.

Int J Chron Obstruct Pulmon Dis. 2012;7:127-35. doi: 10.2147/COPD.S29149. Epub 2012 Feb 23.

20.

Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.

Schuetz P, Müller B, Christ-Crain M, Stolz D, Tamm M, Bouadma L, Luyt CE, Wolff M, Chastre J, Tubach F, Kristoffersen KB, Burkhardt O, Welte T, Schroeder S, Nobre V, Wei L, Bhatnagar N, Bucher HC, Briel M.

Evid Based Child Health. 2013 Jul;8(4):1297-371. doi: 10.1002/ebch.1927. Review.

PMID:
23877944

Supplemental Content

Support Center